Novo Nordisk CEO, Others to Discuss Trump Tariff Threats With Danish Prime Minister
The head of Ozempic maker Novo Nordisk A/S is among business executives who are meeting the Danish prime minister to discuss ...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
24/7 Wall St15h
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Novo Nordisk's Higher Dose Of Wegovy Shows Roughly 21% Weight Loss
Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...
Thurston Springer Miller Herd & Titak Inc. Buys 271 Shares of Novo Nordisk A/S (NYSE:NVO)
Thurston Springer Miller Herd & Titak Inc. raised its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 52.7% during the fourth quarter, HoldingsChannel.com reports. The fund owned 785 shares of ...
Novo Nordisk A/S (NYSE:NVO) Shares Sold by Brookstone Capital Management
Brookstone Capital Management cut its stake in Novo Nordisk A/S (NYSE:NVO – Free Report) by 9.9% in the fourth quarter, ...
Argus Research Remains a Buy on Novo Nordisk (NVO)
In a report released yesterday, Jasper Hellweg from Argus Research maintained a Buy rating on Novo Nordisk (NVO – Research Report). The ...
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Novo Nordisk A/S (NVO) Stock Forecasts
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and ...
Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug
Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...
manilatimes4d
Novo Nordisk A/S - share repurchase programme
Novo Nordisk expects to repurchase B shares for an amount up to DKK 20 billion during a 12-month period beginning 6 February ...
Does Novo Nordisk A/S (NVO) Have an Attractive Valuation?
ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...